Empagliflozin: A sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes

Dixit, Divisha; Yoon, Youngmin; Volino, Lucio R.; Mansukhani, Rupal Patel

doi:10.2146/ajhp150071

Cited by 5 publications

(3 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 18 ] A study found that after single administration of 300 mg of SOTA, 44 g of glucose was excreted in the urine in 24 hours. [ 19 ] Sugar excreted through the urine can reduce a patient's required insulin dose and; therefore, reduce the patient's dependence on insulin.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus

Chen

Xu²,

Zheng³

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: To systematically evaluate the efficacy and safety of sotagliflozin (SOTA) adjuvant therapy for type 1 diabetes mellitus (T1DM). Methods: Through April 2019, the Web of Science, PubMed, Cochrane Library, Embase, and China National Knowledge Infrastructure databases were electronically searched to identify randomized controlled trials exploring SOTA adjuvant therapy for T1DM. Strict screening and quality evaluations of the obtained literature were performed independently by 2 researchers. Outcome indexes were extracted, and a meta-analysis of the data was performed using Revman 5.3 software. Results: A total of 7 randomized controlled trials were included. The meta-analysis results showed that compared with the patients in the placebo group, the patients in the SOTA group had a lower hemoglobin A1c (mean difference [MD] = −0.28, 95% confidence interval [CI] [−0.34, −0.22], P < .01), lower total daily insulin use (MD = −8.89, 95% CI [−11.64, −6.13], P < .01), faster weight loss (MD = −3.03, 95% CI [−3.79, −2.26], P < .01), better fasting blood glucose and 2-hour postprandial blood glucose control (MD = −0.75, 95% CI [−1.04, −0.45], P < .01; MD = −2.42, 95% CI [−3.17, −1.67], P < .01), and a higher rate of well-controlled glucose levels (relative risk = 1.75, 95% CI [1.55, 1.99], P < .01), while no significant difference in the incidence of severe hypoglycemic events was found between the SOTA and placebo groups (risk difference [RD] = −0.01, 95% CI [−0.02, 0.00], P = .13). The incidence of diabetic ketoacidosis was higher in the SOTA group than in the placebo group (RD = 0.03, 95% CI [0.02, 0.04], P < .01). The incidence of genital mycotic infection was higher in the SOTA group than in the placebo group (RD = 0.06, 95% CI [0.05, 0.08], P < .01). No significant difference in the incidence of urinary tract infections was detected between the SOTA group and the placebo group (RD = 0.00, 95% CI [−0.01, 0.01], P = 0.97). Conclusions: SOTA is a potential drug for the treatment of T1DM and is effective for controlling blood sugar. The main adverse reactions to SOTA are genital mycotic infections and diabetic ketoacidosis. We must further assess the severity of diabetic ketoacidosis caused by SOTA.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of sotagliflozin adjuvant therapy for type 1 diabetes mellitus

Chen

Xu²,

Zheng³

et al. 2020

Medicine

View full text Add to dashboard Cite

show abstract

“…Эмпаглифлозин показал положительное влияние на уровень артериально-го давления [20]. Безопасность эмпаглифлозина изучалась в исследовании EMPA-REG, в котором показано благопри-ятное влияние этого ингибитора SGLT2 на сердечно-сосу-дистую систему.…”

Section: но-сосудистые исходы: Savor-timi (саксаглиптин) Examine (алunclassified

Cardiovascular Safety in Therapy of Diabetes Mellitus Type 2

Вербовой¹,

Pashentseva²,

Долгих³

et al. 2016

Med. sov.

View full text Add to dashboard Cite

“…A empagliflozina (Figura 2) é um inibidor potente e seletivo do SGLT2 para o tratamento da DMT2 em adultos, que está aprovado na Europa, nos EUA e em outros mercados [11]. Em 2016, a FDA aprovou uma nova indicação para o Jardiance ® (empagliflozina) na redução do risco de morte cardiovascular em pacientes adultos com DMT2 e doença cardiovascular [12].…”

Section: Introductionunclassified